SDSally Demirdjian

Sally Demirdjian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sally Demirdjian has a total of 77 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers

    Lenacapavir treatment–emergent HIV-1 capsid resistance mutations are frequently associated with replication defects

    by Nina Pennetzdorfer, Vidula Naik, Sally Demirdjian, Matthew R. Hendricks, Cooper S. Jamieson, Jason K. Perry, Laurie A. VanderVeen, Stephen R. Yant, Hadas Dvory-Sobol, Onyema Ogbuagu, et al.

    Lenacapavir (LEN) is a long-acting HIV-1 capsid inhibitor that binds to the HIV-1 capsid protein with picomolar antiviral activity, disrupting its function and inhibiting viral replication. Here, we identified capsid mutations in samples from individuals treated with LEN across two clinical trials that were considered potential LEN resistance–associated mutations. The gag encoding regions of clinical isolates with capsid mutations, as well as associated site-directed mutants, were cloned into the infectious molecular clone pXXLAI and pNL4-3-JRFL-secNLuc, encoding replication-competent HIV-1. Their effects on LEN susceptibility, replication kinetics, and three-dimensional capsid structure were investigated. Phenotypic analyses of the HIV-1 clinical isolates and site-directed mutants revealed that all resistance-associated mutations decreased LEN susceptibility to various degrees but were frequently associated with substantial replication defects. Structural modeling confirmed that LEN binding in the binding pocket was altered in the presence of capsid mutations, with predicted binding affinity changes correlating with observed potency shifts. These findings provide insights into LEN-resistance mechanisms and underscore the unusually high fitness costs associated with treatment-emergent capsid mutations.


  • Open Access

    Resistance Analysis of Low-Level Virologic Rebound During HIV-1 Treatment With Lenacapavir and Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab

    by Lisa Selzer, Sally Demirdjian, Brie Falkard, Jiani Li, Ross Martin, Sean E Collins, Joseph Eron, Laurie A VanderVeen, Christian Callebaut

    Background: High rates of virologic suppression were observed in the Phase 1b study (NCT04811040) investigating lenacapavir and two broadly neutralizing antibodies (bNAb), teropavimab (30 mg/kg) and zinlirvimab (10 or 30 mg/kg), in virologically suppressed people with HIV-1 susceptible (IC90 ≤ 2 μg/mL) to both (primary cohort, n = 20) or either (pilot cohort, n = 10) bNAb. We describe resistance analyses through Week (W) 26. Methods: Post-baseline resistance analyses were conducted at virologic failure, and exploratory resistance analyses performed for participants with virologic rebound. Low copy number genotyping methods for capsid and a 1 kb stretch of gp120 from rebound virus were developed, and phenotypic susceptibility assessed. Results: Virologic failure was observed in 1/30 participants. This primary cohort participant had HIV RNA 155 copies/mL at W16 and developed Q67H in capsid (lenacapavir fold-change 4.7), without resistance to bNAbs; the participant resuppressed on oral antiretrovirals. Two pilot cohort participants, experienced virologic rebound at W26 (55 and 72 copies/mL) and restarted oral antiretrovirals. In exploratory analyses, neither had emergent lenacapavir resistance or altered bNAb susceptibility. Conclusions: Lenacapavir, teropavimab, and zinlirvimab maintained a high rate of virologic suppression through W26, with rare emergent lenacapavir resistance and no bNAb resistance, supporting further Phase 2 evaluation.


  • Open Access

    Phenotypic Characterization of Replication‐Impaired Lenacapavir‐Resistant HIV Clinical Isolates

    by Sally Demirdjian, Vidula Naik, Nicolas Margot, Brie Falkard, Christian Callebaut

    Lenacapavir (LEN) is a potent, first‐in‐class long‐acting HIV‐1 capsid (CA) inhibitor, approved for treatment of people with multi‐drug resistant HIV in combination with other antiretrovirals. In clinical studies with LEN, the CA resistance‐associated mutations (RAMs) M66I, Q67H/K/N, K70H/N/R/S, N74D/H/K, A105S/T, and T107A/C/N/S were observed. Phenotypic analyses of these CA mutants were possible in single cycle (SC) PhenoSense Gag‐Pro assays; however, most CA mutants exhibited severely impaired replication capacity (RC), rendering phenotyping with multicycle (MC) MT‐2 cytopathic assays unsuccessful for many. Here, we developed and optimized a novel MC phenotyping assay using a Rev‐dependent HIV reporter cell line, Rev‐CEM‐Luc/GFP (RevLun assay), to further characterize these replication‐impaired LEN‐resistant HIV CA mutants. HIV Gag‐Protease fragments from patients' plasma samples with CA RAMs and associated site‐directed mutants were cloned into the pXXLAI HIV molecular clone, and replicative viral supernatants were evaluated in MT‐2 and RevLun MC assays, with readouts of cytopathic effect and reporter gene expression, respectively. Viruses were also evaluated in the SC assay. We successfully phenotyped CA mutants in RevLun that were noninfectious in MT‐2 assay, including clinical isolates containing M66I in various genetic contexts and combinations of LEN RAMs. LEN susceptibility in the RevLun MC assay aligned with data in the SC PhenoSense Gag‐Pro assay and MC MT‐2 assay when available. All viruses with LEN RAMs remained sensitive to other HIV drug classes. Using a sensitive HIV‐dependent reporter system enhanced our ability to assess the phenotypes of viruses with low RC, allowing for further investigation into LEN resistance and CA RAMs.


  • Open Access

    Lack of activity of HIV-1 integrase strand-transfer inhibitors on recombinase activating gene (RAG) activity at clinically relevant concentrations

    by Sally Demirdjian, Vincent N. Duong, Jennifer N. Byrum, Arabinda Nayak, Cooper B. McKinney, Jason K. Perry, Christian Callebaut, Karla K. Rodgers, Brie Falkard, Joy Y. Feng

    Human immunodeficiency virus 1 (HIV-1) infection remains a global health concern, with nearly 30 million people on antiretroviral (ARV) treatment. Integrase strand-transfer inhibitors (INSTIs) that block HIV-1 integrase are crucial components of first-line combination ARV therapies recommended in most international guidelines and have significantly improved HIV-1 treatment due to their efficacy and safety. This study evaluates potential off-target effects of INSTIs on recombinase activating genes (RAG1 and RAG2), which are essential for adaptive immune system function. We performed a comprehensive assessment of the off-target effects of clinically approved INSTIs on RAG activity, utilizing both biochemical and cellular assays. We purified the first catalytically active recombinant human core RAG1–RAG2 complex and tested it in the presence of the co-factor human HMGB1 protein for the gel-based biochemical RAG DNA cleavage assay. Additionally, we optimized an extrachromosomal V(D)J recombination cellular assay using murine mCherry-core RAG1, full-length murine mCherry-RAG2, and a plasmid substrate green fluorescent protein (GFP) reporter system, transfecting them into cells in the absence or presence of inhibitors. This setup enabled high-throughput analysis of V(D)J recombination for multiple compounds in a dose–response manner via flow cytometry. Physiologically relevant concentrations of INSTIs were examined for their potential impact on RAG activity and V(D)J recombination, with approved INSTIs showing minimal to no effects on recombinase activity. Consequently, the findings support the continued use of INSTIs in HIV-1 treatment without substantial concern for adverse effects on V(D)J recombination and immune system function. IMPORTANCE: INSTIs are a crucial component of antiretroviral treatments for HIV-1 infection. This study provides a careful and thorough analysis of the impact of approved INSTIs on recombinase activating gene (RAG1 and RAG2) activity, which plays a pivotal role in the adaptive immune system. The concentrations tested were derived from several clinical studies and accounted for the maximum free fraction of the drug available in patients. This approach ensures that our findings are directly applicable to clinical scenarios by providing meaningful insights into the potential drug side effects in patients. We developed biochemical and cellular assays to measure the impact of INSTIs on RAG activity. All tested INSTIs did not inhibit RAG at supratherapeutic concentrations in the RAG1/RAG2 biochemical cleavage and cellular V(D)J recombination assays. Our assessment supports the continued use of INSTIs in HIV-1 treatments without concern for adverse effects.


  • Structure, DFT studies, magnetism and biological activity of bis[(µ-azido)-chloro-(1,10-phenanthroline)-copper(II)] complex

    by Hassan H. Hammud, Ulrich Kortz, Saurav Bhattacharya, Sally Demirdjian, Essa Hariri, Samih Isber, Eun Sang Choi, Babak Mirtamizdoust, Mohamad Mroueh, Costantine F. Daher


  • Distinct Contributions of CD18 Integrins for Binding and Phagocytic Internalization of Pseudomonas aeruginosa

    by Sally Demirdjian, Daniel Hopkins, Nadia Cumbal, Craig T. Lefort, Brent Berwin

    Phagocytosis is the key mechanism for host control ofPseudomonas aeruginosa, a motile Gram-negative, opportunistic bacterial pathogen which frequently undergoes adaptation and selection for traits that are advantageous for survival. One such clinically relevant adaptation is the loss of bacterial motility, observed within chronic infections, that is associated with increased antibiotic tolerance and phagocytic resistance. Previous studies using phagocytes from a leukocyte adhesion deficiency type 1 (LAD-I) patient identified CD18 as a putative cell surface receptor for uptake of liveP. aeruginosa.


  • Open Access

    Motility-Independent Formation of Antibiotic-Tolerant Pseudomonas aeruginosa Aggregates

    by Sally Demirdjian, Hector Sanchez, Daniel Hopkins, Brent Berwin

    In this work, we have investigated the role of bacterial motility with regard to antibiotic-tolerant bacterial aggregate formation. Previous work has convincingly demonstrated that P. aeruginosa flagellar motility promotes the formation of surface-adhered biofilms in many systems. In contrast, aggregate formation by P. aeruginosa was observed for nonmotile but not for motile cells in the presence of an exogenous scaffold. Here, we demonstrate that both wild-type P. aeruginosa and mutants that genetically lack motility spontaneously form antibiotic-tolerant aggregates in the absence of an exogenously added scaffold. Additionally, we also demonstrate that wild-type (WT) and nonmotile P. aeruginosa bacteria can coaggregate, shedding light on potential physiological interactions and heterogeneity of aggregates.


  • Phosphatidylinositol-(3,4,5)-Trisphosphate Induces Phagocytosis of Nonmotile Pseudomonas aeruginosa

    by Sally Demirdjian, Daniel Hopkins, Hector Sanchez, Michael Libre, Scott A. Gerber, Brent Berwin

    Pathogenic bacteria that establish chronic infections in immunocompromised patients frequently undergo adaptation or selection for traits that are advantageous for their growth and survival. Clinical isolates of Pseudomonas aeruginosa , a Gram-negative, opportunistic bacterial pathogen, exhibit a temporal transition from a motile to a nonmotile phenotype through loss of flagellar motility during the course of chronic infection.


  • The effect of loss of O-antigen ligase on phagocytic susceptibility of motile and non-motile Pseudomonas aeruginosa

    by Sally Demirdjian, Kristin Schutz, Matthew J. Wargo, Joseph S. Lam, Brent Berwin


  • Acidosis increases the susceptibility of respiratory epithelial cells toPseudomonas aeruginosa-induced cytotoxicity

    by Iviana M. Torres, Sally Demirdjian, Jennifer Vargas, Britton C. Goodale, Brent Berwin

    Bacterial infection can lead to acidosis of the local microenvironment, which is believed to exacerbate disease pathogenesis; however, the mechanisms by which changes in pH alter disease progression are poorly understood. We test the hypothesis that acidosis enhances respiratory epithelial cell death in response to infection with Pseudomonas aeruginosa. Our findings support the idea that acidosis in the context of P. aeruginosa infection results in increased epithelial cell cytotoxicity due to ExoU intoxication. Importantly, enforced maintenance of neutral pH during P. aeruginosa infection demonstrates that cytotoxicity is dependent on the acidosis. Investigation of the underlying mechanisms revealed that host cell cytotoxicity correlated with increased bacterial survival during an acidic infection that was due to reduced bactericidal activity of host-derived antimicrobial peptides. These findings extend previous reports that the activities of antimicrobial peptides are pH-dependent and provide novel insights into the consequences of acidosis on infection-derived pathology. Therefore, this report provides the first evidence that physiological levels of acidosis increase the susceptibility of epithelial cells to acute Pseudomonas infection and demonstrates the benefit of maintaining pH homeostasis during a bacterial infection.